Eli Lilly Just Launched Its $149 Obesity Pill – Eli Lilly (NYSE:LLY)
Eli Lilly and Co. (NYSE:LLY) on Wednesday announced that Foundayo (orforglipron) is now available to adults with obesity…
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a…
Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer’s – Novo Nordisk (NYSE:NVO)
Upcoming data from Novo Nordisk A/S (NYSE:NVO) early next month could offer the clearest signal yet on whether…
Novo Nordisk Leans Into Affordability Amid Rising Competition – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are…
Novo Nordisk’s $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker – Novo Nordisk (NYSE:NVO)
In a presentation at the American Heart Association’s (AHA’s) 2025 Scientific Sessions, researchers on Tuesday shared data from…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets – Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…